HUP0204159A2 - Prosztaglandin-készítmények és alkalmazásuk erekciós zavarok kezelésére szolgáló gyógyszerek előállítására - Google Patents
Prosztaglandin-készítmények és alkalmazásuk erekciós zavarok kezelésére szolgáló gyógyszerek előállításáraInfo
- Publication number
- HUP0204159A2 HUP0204159A2 HU0204159A HUP0204159A HUP0204159A2 HU P0204159 A2 HUP0204159 A2 HU P0204159A2 HU 0204159 A HU0204159 A HU 0204159A HU P0204159 A HUP0204159 A HU P0204159A HU P0204159 A2 HUP0204159 A2 HU P0204159A2
- Authority
- HU
- Hungary
- Prior art keywords
- preparation
- compositions
- erectile dysfunction
- prostaglandin
- treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 208000010228 Erectile Dysfunction Diseases 0.000 title abstract 2
- 201000001881 impotence Diseases 0.000 title abstract 2
- 150000003180 prostaglandins Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 abstract 1
- -1 aliphatic ester Chemical class 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 150000002634 lipophilic molecules Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A találmány az alábbi anyagok alkalmazása erekciózavar kezeléséreszolgáló gyógyászati készítmény előállítására ilyen kezelésre szorulópáciensek számára, melynek során a gyógyászati készítményt a páciensfossa naviculárisába juttatják: a) prosztaglandin b) penetrációtelősegítő szer, amely az alábbiakat tartalmazó csoport tagja: alkil-2-(N,N-diszubsztituált amino)-alkanoát, (N,N-diszubsztituált)-alkanol-alkanoát, ezek gyógyászatilag alkalmazható sói és keverékei; c)poliszacharid gumi; d) lipofil vegyület, amely az alábbiakattartalmazó csoport tagja: alifás 1-8 szénatomos alkohol, alifás 8-30szénatomszámú észter és ezek keverékei; és e) savas pufferrendszer. Atalálmány tárgyát képezi továbbá a fenti alkalmazás segítségévelelőállított készítmény is. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/480,738 US6323241B1 (en) | 2000-01-10 | 2000-01-10 | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
PCT/US2001/000852 WO2001051053A1 (en) | 2000-01-10 | 2001-01-10 | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0204159A2 true HUP0204159A2 (hu) | 2003-04-28 |
HUP0204159A3 HUP0204159A3 (en) | 2005-03-29 |
Family
ID=23909154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0204159A HUP0204159A3 (en) | 2000-01-10 | 2001-01-10 | Prostaglandin compositions and their use for preparation of pharmaceutical compositions for treatment male erectile dysfunction |
Country Status (20)
Country | Link |
---|---|
US (1) | US6323241B1 (hu) |
EP (1) | EP1255552B1 (hu) |
JP (2) | JP2003519657A (hu) |
KR (1) | KR100614361B1 (hu) |
CN (1) | CN1394140A (hu) |
AT (1) | ATE290383T1 (hu) |
AU (1) | AU760576C (hu) |
BE (1) | BE2014C001I2 (hu) |
BR (1) | BR0107478A (hu) |
CA (1) | CA2395217C (hu) |
DE (1) | DE60109274T2 (hu) |
ES (1) | ES2236245T3 (hu) |
HK (1) | HK1047700B (hu) |
HU (1) | HUP0204159A3 (hu) |
IL (2) | IL150306A0 (hu) |
MX (1) | MXPA02006758A (hu) |
PT (1) | PT1255552E (hu) |
TR (1) | TR200201769T2 (hu) |
WO (1) | WO2001051053A1 (hu) |
ZA (1) | ZA200205433B (hu) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR1002847B (el) | 1997-05-06 | 1998-01-27 | Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως | |
US6414028B1 (en) * | 1997-11-05 | 2002-07-02 | Nexmed Holdings, Inc. | Topical compositions containing prostaglandin E1 |
US20050004226A1 (en) * | 1998-12-10 | 2005-01-06 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
EA008720B1 (ru) * | 1998-12-10 | 2007-06-29 | Нексмед (Холдингс), Инк. | Применение композиции на основе простагландина для лечения расстройства сексуального возбуждения у женщин |
US6825234B2 (en) | 1998-12-10 | 2004-11-30 | Nexmed (Holdings) , Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US20040110843A1 (en) * | 2000-01-10 | 2004-06-10 | Nexmed (Holdings), Inc. | Methods of treatment of male erectile dysfunction |
US6693135B2 (en) * | 2000-01-10 | 2004-02-17 | Nexmed (Holdings) Incorporated | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
US7105571B2 (en) * | 2000-01-10 | 2006-09-12 | Nexmed Holdings, Inc. | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
WO2003063776A2 (en) | 2002-01-25 | 2003-08-07 | Modular Properties Ltd | Methods and compositions for treating male erectile dysfunction |
US20090035221A1 (en) * | 2002-01-25 | 2009-02-05 | Ramsey Sallis | Methods and Compositions for Treatment of Erectile Dysfunction |
US20090257956A1 (en) * | 2002-01-25 | 2009-10-15 | Ramsey Sallis | Treatment Method for Treatment of Erectile Dysfunction and Premature Ejaculation |
IL162154A0 (en) * | 2002-02-15 | 2005-11-20 | Nexmed Holdings Inc | Prostagandin composition for the treatment of erectile dysfunction |
KR20050057245A (ko) * | 2002-09-06 | 2005-06-16 | 넥스메드 홀딩스 인코포레이티드 | 남성 발기 부전을 치료하는 방법 |
GB0222522D0 (en) | 2002-09-27 | 2002-11-06 | Controlled Therapeutics Sct | Water-swellable polymers |
US6841574B2 (en) * | 2003-01-03 | 2005-01-11 | Nexmed Holdings, Inc. | Topical stabilized prostaglandin E compound dosage forms |
US20040241243A1 (en) * | 2003-03-21 | 2004-12-02 | Nexmed (Holdings) Inc. | Angiogenesis promotion by prostaglandin compositions and methods |
WO2004084878A1 (en) * | 2003-03-21 | 2004-10-07 | Nexmed (Holdings), Inc. | Compositions and methods for treatment of premature ejaculation |
WO2004084908A1 (en) * | 2003-03-21 | 2004-10-07 | Nexmed (Holdings), Inc. | Prostaglandin compositions for the treatment of erectile dysfunction |
KR20050119187A (ko) * | 2003-04-02 | 2005-12-20 | 넥스메드 홀딩스 인코포레이티드 | 프로스타글란딘 조성물 및 이의 혈관연축 치료용 용도 |
US20050159985A1 (en) * | 2003-11-21 | 2005-07-21 | Bertram Carl T. | System and method of stratifying intervention groups and comparison groups based on disease severity index scores and ranges |
GB0417401D0 (en) | 2004-08-05 | 2004-09-08 | Controlled Therapeutics Sct | Stabilised prostaglandin composition |
US7655659B2 (en) * | 2004-08-19 | 2010-02-02 | Applied Genetics Incorporated Dermatics | Biomimetic of Evodia rutaecarpa fruit extract for amelioration of inflammation |
GB0613333D0 (en) | 2006-07-05 | 2006-08-16 | Controlled Therapeutics Sct | Hydrophilic polyurethane compositions |
GB0613638D0 (en) | 2006-07-08 | 2006-08-16 | Controlled Therapeutics Sct | Polyurethane elastomers |
GB0620685D0 (en) | 2006-10-18 | 2006-11-29 | Controlled Therapeutics Sct | Bioresorbable polymers |
US9005183B2 (en) * | 2007-05-16 | 2015-04-14 | Health Knight, Llc | System and method for treating erectile dysfunction |
KR102004552B1 (ko) * | 2010-12-02 | 2019-10-01 | 넥스메드 홀딩스 인코포레이티드 | 도데실 2-(n,n-다이메틸아미노)-프로피오네이트의 활성 거울상체 |
CA2838109C (en) | 2011-04-07 | 2020-06-09 | Nexmed Holdings, Inc. | Topical semisolid prostaglandin e1 composition for treating raynaud's disease |
US10226418B2 (en) | 2014-05-12 | 2019-03-12 | Susie Q, Ltd. | Arginine-containing topical composition |
CA2974113A1 (en) | 2015-01-20 | 2016-07-28 | Xoc Pharmaceuticals, Inc. | Isoergoline compounds and uses thereof |
CN113149982A (zh) | 2015-01-20 | 2021-07-23 | Xoc制药股份有限公司 | 麦角灵化合物及其用途 |
EP3266458A1 (en) | 2016-07-05 | 2018-01-10 | Fagron B.V. | Method and composition and kit for treating erectile dysfunction |
WO2018223065A1 (en) | 2017-06-01 | 2018-12-06 | Xoc Pharmaceuticals, Inc. | Ergoline derivatives for use in medicine |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2818855A (en) | 1954-02-11 | 1958-01-07 | Anthony P Miller | Surgical device |
BE790840A (fr) | 1971-11-01 | 1973-04-30 | Upjohn Co | Solutions de medicaments instables et leur preparation |
US4127118B1 (en) | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
US4254145A (en) | 1978-08-16 | 1981-03-03 | American Cyanamid Company | Topical application of prostaglandin hypotensive agents |
US4311707A (en) | 1979-02-12 | 1982-01-19 | American Cyanamid Company | Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions |
US4801587A (en) | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
US5256652A (en) | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
US4980378A (en) | 1988-06-01 | 1990-12-25 | Odontex, Inc. | Biodegradable absorption enhancers |
SE463851B (sv) | 1988-09-02 | 1991-02-04 | Amsu Ltd | Komposition foer behandling av erektil dysfunktion via uretra |
NZ270871A (en) | 1990-04-25 | 1999-05-28 | Vivus Inc | Method for treating erectile dysfunction |
US5242391A (en) | 1990-04-25 | 1993-09-07 | Alza Corporation | Urethral insert for treatment of erectile dysfunction |
US5380760A (en) | 1993-11-19 | 1995-01-10 | Minnesota Mining And Manufacturing Company | Transdermal prostaglandin composition |
TR199700930T2 (xx) | 1995-03-14 | 1998-07-21 | Vivus Incorporated | Ereksiyon bozuklu�unu �nlemek i�in y�ntem ve kit. |
WO1999002147A1 (en) * | 1997-07-09 | 1999-01-21 | Androsolutions, Inc. | Improved methods and compositions for treating male erectile dysfunction |
CA2305394C (en) * | 1997-10-28 | 2006-12-12 | Vivus, Incorporated | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
US6046244A (en) * | 1997-11-05 | 2000-04-04 | Nexmed Holdings, Inc. | Topical compositions for prostaglandin E1 delivery |
US5942545A (en) | 1998-06-15 | 1999-08-24 | Macrochem Corporation | Composition and method for treating penile erectile dysfunction |
US6486207B2 (en) | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US6102849A (en) | 1999-04-03 | 2000-08-15 | Hakac; John R. | Non-surgical penile prosthesis |
-
2000
- 2000-01-10 US US09/480,738 patent/US6323241B1/en not_active Expired - Lifetime
-
2001
- 2001-01-10 MX MXPA02006758A patent/MXPA02006758A/es active IP Right Grant
- 2001-01-10 JP JP2001551477A patent/JP2003519657A/ja active Pending
- 2001-01-10 AU AU29349/01A patent/AU760576C/en not_active Expired
- 2001-01-10 PT PT01942300T patent/PT1255552E/pt unknown
- 2001-01-10 KR KR1020027008845A patent/KR100614361B1/ko active IP Right Grant
- 2001-01-10 HU HU0204159A patent/HUP0204159A3/hu active IP Right Revival
- 2001-01-10 CA CA002395217A patent/CA2395217C/en not_active Expired - Lifetime
- 2001-01-10 EP EP01942300A patent/EP1255552B1/en not_active Expired - Lifetime
- 2001-01-10 WO PCT/US2001/000852 patent/WO2001051053A1/en active IP Right Grant
- 2001-01-10 CN CN01803447A patent/CN1394140A/zh active Pending
- 2001-01-10 AT AT01942300T patent/ATE290383T1/de active
- 2001-01-10 DE DE60109274T patent/DE60109274T2/de not_active Expired - Lifetime
- 2001-01-10 ES ES01942300T patent/ES2236245T3/es not_active Expired - Lifetime
- 2001-01-10 TR TR2002/01769T patent/TR200201769T2/xx unknown
- 2001-01-10 IL IL15030601A patent/IL150306A0/xx active IP Right Grant
- 2001-01-10 BR BR0107478-4A patent/BR0107478A/pt not_active Application Discontinuation
-
2002
- 2002-06-18 IL IL150306A patent/IL150306A/en unknown
- 2002-07-08 ZA ZA200205433A patent/ZA200205433B/xx unknown
- 2002-12-13 HK HK02109079.3A patent/HK1047700B/zh not_active IP Right Cessation
-
2007
- 2007-07-18 JP JP2007186380A patent/JP2007302690A/ja active Pending
-
2014
- 2014-01-06 BE BE2014C001C patent/BE2014C001I2/fr unknown
Also Published As
Publication number | Publication date |
---|---|
AU760576C (en) | 2004-04-08 |
KR100614361B1 (ko) | 2006-08-18 |
IL150306A (en) | 2007-06-03 |
CA2395217C (en) | 2004-10-26 |
ATE290383T1 (de) | 2005-03-15 |
US6323241B1 (en) | 2001-11-27 |
MXPA02006758A (es) | 2008-09-12 |
CN1394140A (zh) | 2003-01-29 |
HK1047700A1 (en) | 2003-03-07 |
JP2007302690A (ja) | 2007-11-22 |
JP2003519657A (ja) | 2003-06-24 |
PT1255552E (pt) | 2005-06-30 |
AU760576B2 (en) | 2003-05-15 |
ZA200205433B (en) | 2003-11-26 |
HUP0204159A3 (en) | 2005-03-29 |
ES2236245T3 (es) | 2005-07-16 |
DE60109274D1 (de) | 2005-04-14 |
EP1255552B1 (en) | 2005-03-09 |
IL150306A0 (en) | 2002-12-01 |
TR200201769T2 (tr) | 2002-11-21 |
BR0107478A (pt) | 2002-09-03 |
KR20020073498A (ko) | 2002-09-26 |
CA2395217A1 (en) | 2001-07-19 |
AU2934901A (en) | 2001-07-24 |
BE2014C001I2 (hu) | 2020-01-30 |
HK1047700B (zh) | 2005-05-27 |
WO2001051053A1 (en) | 2001-07-19 |
DE60109274T2 (de) | 2006-02-09 |
EP1255552A1 (en) | 2002-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0204159A2 (hu) | Prosztaglandin-készítmények és alkalmazásuk erekciós zavarok kezelésére szolgáló gyógyszerek előállítására | |
HUP0401816A2 (hu) | Prosztaglandin-készítmények és alkalmazásuk erekciós zavarok kezelésére szolgáló gyógyszerek előállítására | |
HUP0201145A2 (hu) | Prosztaglandin E1 leadására szolgáló helyileg adagolandó készítmények | |
DE69532678D1 (de) | Arzneizubereitungen enthaltend nicht-steroidale entzündungshemmende Arzneimittel | |
DK1227806T3 (da) | Farmaceutisk præparat indeholdende tolterodin og dets anvendelse | |
EP1243269A3 (en) | Opioid formulations having extended controlled release | |
UA42061C2 (uk) | Фармацевтична композиція для перорального введення, що містить інгібітори протонного насоса | |
AR065827A2 (es) | Formas de dosificacion de liberacion sostenida de sertralina, sales de sertralina, composicion farmaceutica, procedimiento y preparacion y su uso en terapia | |
CO4750658A1 (es) | Formulaciones farmaceuticas y procedimientos que comprenden amoxicilina y una sal de acido clavulanico | |
HUP0004300A2 (hu) | (S)-N-Etil-3-[1-(dimetil-amino)-etil]-N-metil-fenil-karbamátot és antioxidánst tartalmazó gyógyszerkészítmény | |
RU94045950A (ru) | Фармацевтический препарат и способ его приготовления | |
ATE202926T1 (de) | Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung | |
ATE198152T1 (de) | Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe | |
NO306894B1 (no) | Anvendelse av galanthamin for fremstilling av en farmasöytisk formulering for behandling av nikotinavhengighet | |
HUP9801227A2 (hu) | Monoamin-oxidáz B inhibitorokból álló gyógyászati készítmények és alkalmazásuk | |
ATE298324T1 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
CA2136404A1 (fr) | Composition solide mucoadhesive, therapeutique ou hygienique, pour administration par application sur la muqueuse buccale ou nasale | |
ATE173923T1 (de) | Oralanzuwendende flüssige arzneizubereitung enthaltend 2-(4-isobutylphenyl)propionsäure | |
HUP0105481A2 (hu) | Klaritromicint vagy származékait tartalmazó gyógyászati készítmények és eljárás előállításukra, valamint alkalmazásuk | |
ATE213633T1 (de) | Lamotrigin haltiges arzneimittel | |
US4892877A (en) | Antitussive liquid compositions containing phenol | |
DE69928806D1 (de) | (-)-pseudoephedrin als sympathomimetisches arzneimittel | |
JP2005187328A (ja) | イブプロフェン含有解熱鎮痛組成物、及び感冒薬 | |
JPS6411613B2 (hu) | ||
JP2548686B2 (ja) | 外用薬剤組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished | ||
NF4A | Restoration of patent protection | ||
GB9A | Succession in title |
Owner name: FERRING INTERNATIONAL CENTER S.A., CH Free format text: FORMER OWNER(S): NEXMED HOLDINGS, INC., US |